Sign up online today & collaborate
or click here to find out more
AstraZeneca and Eli Lilly are to combine two of their cancer drugs in a new clinical trial against solid tumours in the latest sign that such cocktails may be the way forward in fighting the disease.
AstraZeneca's experimental anti-PD-L1 immunotherapy drug MEDI4736 will be tested alongside Lilly's approved medicine Cyramza, or ramucirumab, the two companies said on Friday.
The early-stage Phase I trial will be run by Lilly but additional details of the collaboration, including tumour types to be studied and financial terms, were not disclosed.
MEDI4736 belongs to a hot new class of treatments designed to boost the immune system in the battle against cancer, while Cyramza is part of an older type of so-called antiangiogenic medicines that starve tumours of blood supply.
For more click here